Bausch Health Companies Inc. (NYSE:BHC – Free Report) – Equities researchers at Zacks Research reduced their Q4 2023 EPS estimates for Bausch Health Companies in a research report issued on Wednesday, September 6th. Zacks Research analyst E. Bagri now expects that the company will post earnings of $1.00 per share for the quarter, down from their prior forecast of $1.01. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.29 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2024 earnings at $0.91 EPS, FY2024 earnings at $3.54 EPS and FY2025 earnings at $4.06 EPS.
A number of other brokerages have also recently issued reports on BHC. TD Cowen cut shares of Bausch Health Companies from an “outperform” rating to a “market perform” rating in a report on Friday, June 16th. StockNews.com initiated coverage on shares of Bausch Health Companies in a report on Thursday, August 17th. They set a “hold” rating for the company. Royal Bank of Canada boosted their price objective on shares of Bausch Health Companies from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Monday, July 24th. Finally, Jefferies Financial Group boosted their price objective on shares of Bausch Health Companies from $7.00 to $9.50 in a report on Monday, May 22nd.
Bausch Health Companies Trading Up 2.6 %
BHC opened at $8.64 on Monday. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -16.94 and a beta of 0.98. The firm has a 50 day simple moving average of $8.68 and a 200 day simple moving average of $8.01. The company has a debt-to-equity ratio of 74.20, a current ratio of 1.12 and a quick ratio of 0.81. Bausch Health Companies has a fifty-two week low of $5.57 and a fifty-two week high of $10.23.
Bausch Health Companies (NYSE:BHC – Get Free Report) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.06. The business had revenue of $2.17 billion during the quarter, compared to the consensus estimate of $2.04 billion. Bausch Health Companies had a negative net margin of 2.23% and a positive return on equity of 411.18%.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. GTS Securities LLC acquired a new position in shares of Bausch Health Companies in the second quarter valued at approximately $931,000. Rokos Capital Management LLP acquired a new position in Bausch Health Companies during the second quarter worth $14,078,000. Clearline Capital LP boosted its holdings in Bausch Health Companies by 28.5% during the second quarter. Clearline Capital LP now owns 1,167,343 shares of the company’s stock worth $9,339,000 after purchasing an additional 258,876 shares during the last quarter. Gamco Investors INC. ET AL boosted its holdings in Bausch Health Companies by 2.8% during the second quarter. Gamco Investors INC. ET AL now owns 1,415,945 shares of the company’s stock worth $11,328,000 after purchasing an additional 38,700 shares during the last quarter. Finally, Redwood Investment Management LLC boosted its holdings in Bausch Health Companies by 10.8% during the second quarter. Redwood Investment Management LLC now owns 497,502 shares of the company’s stock worth $3,769,000 after purchasing an additional 48,560 shares during the last quarter. Institutional investors and hedge funds own 74.56% of the company’s stock.
Insider Activity
In other news, EVP Seana Carson sold 6,685 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $8.28, for a total value of $55,351.80. Following the completion of the transaction, the executive vice president now owns 385,213 shares in the company, valued at $3,189,563.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 13.75% of the company’s stock.
About Bausch Health Companies
Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Read More
- Five stocks we like better than Bausch Health Companies
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 9/4 – 9/8
- The Role Economic Reports Play in a Successful Investment Strategy
- The Best 5 Small Cap AI Companies to Buy Now
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
